Key Development
DK Pharma’s Eskar eye drops have been recognized under the Vietnam National Brand Programme for a second consecutive selection cycle, following their recognition in 2024. Beyond a branding milestone, the development highlights a more consequential industry question: can Vietnamese pharmaceutical manufacturers turn consistent quality systems into stronger market positioning and long-term competitiveness?
The 2026 recognition was announced on October 16 under Ministry of Industry and Trade Decision No. 2136/QĐ-BCT. The programme recognized 499 products from 227 enterprises. DK Pharma also received recognition for its Aladka nasal spray, which entered the programme for the first time.
Under the 2026 evaluation framework, quality accounts for 300 of the available 1,000 points. Products must achieve at least 60% of the quality-category score and meet the overall qualifying threshold. Eskar is produced at DK Pharma’s WHO-GMP pharmaceutical facility in Bac Ninh, operating since 2018. The company’s quality-control laboratory holds ISO/IEC 17025:2017 accreditation under VILAS 1275, covering specified chemical, biological and pharmaceutical testing activities.
Why It Matters
- Sterile manufacturing capability is a meaningful pharmaceutical barrier to entry, requiring controlled environments, validated processes and specialized personnel.
- Repeated national brand recognition can reinforce commercial credibility, although it is not equivalent to independent clinical superiority.
- Laboratory competence strengthens manufacturing reliability, supporting validated testing, measurement traceability and informed batch-release decisions.
- Quality systems require recurring investment, making sustainable compliance an operating capability rather than a one-time certification expense.
- Domestic pharmaceutical companies may compete through quality differentiation, reducing dependence on price alone in selected product categories.
Healthcare Insight Analysis
Healthcare Insight believes Eskar’s recognition illustrates how manufacturing quality can become an important strategic asset for Vietnam’s domestic pharmaceutical industry.
For a sterile ophthalmic product, commercial value begins long before the medicine reaches a pharmacy shelf. It begins with the manufacturer’s ability to prevent contamination and demonstrate consistent control over every production batch.
Eye drops are different from conventional oral medicines.
They come into direct contact with sensitive ocular tissues.
Production therefore requires stringent contamination controls, carefully managed manufacturing conditions and reliable quality-assurance processes.
A finished-product test alone cannot compensate for an inadequately controlled production system.
The pharmaceutical value chain becomes:
facility design → controlled manufacturing → environmental monitoring → laboratory testing → qualified batch release → distribution confidence.
1. Sterility is a production-system capability, not a final inspection result
For sterile pharmaceuticals, quality must be designed into the process.
Air-handling systems require maintenance.
Cleanroom conditions require monitoring.
Staff must follow validated procedures.
Equipment must be qualified.
Batch documentation must be complete.
This creates an important economic distinction.
A sterile manufacturing facility is not simply a factory with more expensive equipment. It is an operating system with permanent quality obligations.
The initial investment in facilities is only one part of the cost.
Recurring spending on environmental monitoring, calibration, maintenance, training and quality investigations determines whether compliance can be sustained.
For manufacturers, that capability may support stronger customer confidence and more resilient distribution relationships.
2. GMP and laboratory accreditation create complementary layers of assurance
DK Pharma’s manufacturing and testing systems demonstrate two different components of pharmaceutical quality.
WHO-GMP provides the framework for controlling manufacturing processes and pharmaceutical quality.
ISO/IEC 17025 accreditation addresses technical competence within the accredited scope of laboratory testing.
The distinction matters.
GMP concerns the integrity of how medicines are manufactured. ISO/IEC 17025 addresses the competence of specific laboratory testing activities.
Neither standard should be interpreted as proof that one branded medicine produces better clinical outcomes than a competitor.
Nor does laboratory accreditation automatically cover every test performed by a company; its value must be assessed against the published accreditation scope.
Together, however, these systems can provide a stronger foundation for reliable quality decisions.
3. National recognition can strengthen brand equity—but cannot replace market evidence
The Vietnam National Brand Programme evaluates products using a broader framework than pharmaceutical quality alone.
Its recognition may support visibility, stakeholder confidence and brand differentiation.
However, a national brand award is not equivalent to a new drug approval, an international regulatory authorization or proof of superior therapeutic efficacy.
For healthcare executives and investors, this distinction is essential.
Recognition can influence reputation.
But actual commercial performance depends on patient needs, product positioning, pharmacy availability, competitive pricing and repeat purchasing.
The commercial pathway is:
verified quality capability → stakeholder confidence → channel acceptance → product availability → sustainable demand.
The magnitude of the impact must be established through operating results.
4. Quality investment changes the economics of domestic pharmaceutical competition
In crowded medicine categories, price can become the primary basis of competition.
This creates pressure on margins and may constrain reinvestment in technology.
A quality-led strategy introduces another competitive dimension.
Manufacturers capable of demonstrating reliable production, traceability and technical competence may be better positioned to build long-term relationships with distributors and healthcare institutions.
But quality investment does not guarantee premium pricing.
Quality creates the foundation for differentiation; commercial execution determines whether differentiation generates acceptable returns.
For DK Pharma, the strategic opportunity is to convert manufacturing and laboratory capabilities into sustainable product trust and broader portfolio value.
The relevant performance indicators should include batch-release consistency, deviation and complaint trends, recall frequency, quality-investment productivity and commercial outcomes.
Market Implications
DK Pharma: can strengthen Eskar’s positioning by connecting recognized brand value with transparent manufacturing quality and consistent product performance.
Domestic pharmaceutical manufacturers: face an opportunity to compete through sterile production capability, laboratory competence and reliable quality governance.
Pharmacy chains and distributors: may increasingly evaluate manufacturers on product traceability, quality-system consistency and complaint-handling performance.
Regulators and industry organizations: can encourage greater transparency around manufacturing standards and measurable quality performance without conflating awards with medicine approvals.
Healthcare investors: should examine recurring quality expenditure, manufacturing productivity, regulatory compliance and financial returns rather than brand recognition alone.
ANALYTICAL MATRIX
| Dimension | Current Signal | Opportunity | Key Risk |
| Brand recognition | Eskar recognized in 2024 and 2026 | Stronger brand credibility | Limited evidence of sales impact |
| Sterile manufacturing | WHO-GMP facility in Bac Ninh | Specialized production capability | Contamination and compliance risks |
| Laboratory quality | ISO/IEC 17025, VILAS 1275 | More reliable testing and traceability | Testing-scope limitations |
| Quality investment | Ongoing monitoring and maintenance | Long-term consistency | Higher operating costs |
| Domestic competition | Quality-led product positioning | Reduced dependence on price | Inability to monetize differentiation |
Eskar’s second National Brand recognition is not simply a marketing achievement. It highlights the commercial potential of building pharmaceutical credibility on repeatable manufacturing and laboratory capabilities.
For Vietnam’s pharmaceutical industry, the larger opportunity is to make quality a verifiable and consistently maintained source of competitiveness.
That requires connecting technical standards with product performance, distribution reliability and measurable business outcomes.
The broader industry signal is clear:
domestic pharmaceutical competitiveness will increasingly depend not only on which companies can manufacture medicines, but on which companies can consistently demonstrate the quality of every batch they release.